DESTINY-Breast09: NCT04784715: Phase 3: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer 1L
First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting II Free access Breast Cancer—Metastatic June 04, 2025 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast0
Dec 31, 2025
NeoADAURA: NCT04351555: Phase 3: Osimertinib VS Osimertinib + Chemo VS Chemo Alone - Neoadjuvant Therapy - EGFRm Positive Resectable Non-Small Cell Lung Cancer
First Posted 2020-04-17 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Peer-reviewed journal publication Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer J Clin Oncol Sep 2025 PUBMED JCO NCCN FDA NeoADAURA: NCT04351555: Phase 3: Osimertinib VS Osimertinib + Chemo VS Chemo Alone - Neoadjuvant Therapy - EGFRm Positive Resectable Non-Small Cell Lung Cancer (A Study of Osimertinib With or Without Chemotherapy Versus Che
Dec 15, 2025
TROPION-Breast01: NCT05104866: Phase 3: Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer, treated With 1-2 Prior LOT
First Posted 2021-11-03 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation ESMO 2023 (Annals of Oncology) abstract (LBA11) LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial October 2023 Click here for details AACR 2024 (Cancer Research) abstract (GS02-01) Ab
Dec 15, 2025
TOPAZ-1: NCT03875235: Phase 3: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer
First Posted 2019-03-14 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. 2022 ASCO Gastrointestinal Cancers Symposium Click here for details Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcita
Dec 15, 2022